Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review

BMC Fam Pract. 2019 Nov 15;20(1):157. doi: 10.1186/s12875-019-1047-z.

Abstract

Background: The opioid epidemic is a major public health issue associated with significant overdose deaths. Effective treatments exist, such as the medication buprenorphine, but are not widely available. This narrative review examines the attitudes of primary care providers (PCPs) toward prescribing buprenorphine.

Methods: Narrative review of 20 articles published after the year 2000, using the Consolidated Framework for Implementation Research (CFIR) to organize the findings.

Results: Three of the five CFIR domains ("Intervention Characteristics," "Outer Setting," "Inner Setting") were strongly represented in our analysis. Providers were concerned about the clientele associated with buprenorphine, diversion, and their self-efficacy in prescribing the medication. Some believed that buprenorphine does not belong in the discipline of primary care. Other barriers included philosophical objections and stigma toward substance use disorders. Notably, two studies reported a shift in attitudes once physicians prescribed buprenorphine to actual patients.

Conclusions: Negative attitudes toward buprenorphine encompassed multi-layered concerns, ranging from skepticism about the medication itself, the behaviors of patients with opioid use disorders, and beliefs regarding substance use disorders more generally. We speculate, however, that negative attitudes may be improved by tailoring support strategies that address providers' self-efficacy and level of knowledge.

Keywords: Attitudes; Barriers; Buprenorphine; Primary care providers; Stigma.

Publication types

  • Review

MeSH terms

  • Attitude of Health Personnel*
  • Buprenorphine / therapeutic use*
  • Drug Prescriptions
  • Humans
  • Narcotic Antagonists / therapeutic use*
  • Physicians, Primary Care / psychology*
  • Physicians, Primary Care / statistics & numerical data

Substances

  • Narcotic Antagonists
  • Buprenorphine